ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2385-2392

  Chen, Yue ^a   Zou, Hong ^a   Yang, Li Ying ^a   Li, Yuan ^a   Wang, Li ^a   Hao, Yan ^a   Yang, Ju Lun ^a  

^a KUNMING GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; ER81; Gene therapy; shRNA; Triple negative

Indexed keywords

DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETV1 PROTEIN, HUMAN; MESSENGER RNA; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84872682744     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2385     Document Type: Article

References (42)

1. Baert JL, Monte D, Musgrove EA, et al (1997). Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer, 70, 590-7.
2. Bosc DG, Goueli BS, Janknecht R (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene, 20, 6215-24.
3. Bosc DG, Janknecht R (2002). Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81. J Cell Biochem, 86, 174-83.
4. Brown TA, McKnight SL (1992). Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev, 6, 2502-12.
5. Cai C, Hsieh CL, Omwancha J, et al (2007). ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol, 21, 1835-46.
6. Chen W, Yuan K, Tao ZZ, et al (2011). Deletion of Forkhead Box M1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev, 12, 1785-8.
7. Chi P, Chen Y, Zhang L, et al (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 467, 849-53.
8. Chung CH, Bernard PS, Perou CM (2002). Molecular portraits and the family tree of cancer. Nat Genet, 32, S533-40.
9. Clay CE, Namen AM, Atsumi G, et al (1999). Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis, 20, 1905-11.
10. Crawford HC, Fingleton B, Gustavson MD, et al (2001). The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol, 21, 1370-83.
11. Cui JW, Li Y, Wang C, et al (2012). Knockdown of a proliferationinducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev, 13, 633-6.
12. Dowdy SC, Mariani A, Janknecht R (2003). HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem, 278, 44377-84.
13. Fuchs B, Inwards C, Scully SP, et al (2004). hTERT Is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin Orthop Relat Res, 426, 64-8.
14. Fuchs B, Inwards CY, Janknecht R (2003). Upregulation of the matrix metalloproteinase-1 gene by the Ewing's sarcoma associated EWS-ER81 and EWS-Fli-1 oncoproteins, c-Jun and p300. FEBS Lett, 553, 104-8.
15. Fuchs B, Inwards CY, Janknecht R (2004). Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res, 10, 1344-53.
16. Galang CK, Muller WJ, Foos G, et al (2004). Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem, 279, 11281-92.
17. Goel A, Janknecht R (2003). Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol, 23, 6243-54.
18. Goueli BS, Janknecht R (2004). Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol, 24, 25-35.
19. Ha SA, Lee YS, Shin SM, et al (2009). Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer, 9, 51.
20. Higashino F, Yoshida K, Fujinaga Y, et al (1993). Isolation of a cDNA encoding the adenovirus E1A enhancer binding protein: a new human member of the ets oncogene family. Nucleic Acids Res, 21, 547-53.
21. Holbro T, Civenni G, Hynes NE (2003). The ErbB receptors and their role in cancer progression. Exp Cell Res, 284, 99-110.
22. Jane-Valbuena J, Widlund HR, Perner S, et al (2010). An oncogenic role for ETV1 in melanoma. Cancer Res, 70, 2075-84.
23. Janknecht R (1996). Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol, 16, 1550-6.
24. Janknecht R (2004). On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett, 564, 9-13.
25. Janknecht R (2005). EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene, 363, 1-14.
26. Janknecht R, Ernst WH, Pingoud V, et al (1993). Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J, 12, 5097-104.
27. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
28. Jeon IS, Davis JN, Braun BS, et al (1995). A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene, 10, 1229-34.
29. Lu WC, Liu YN, Kang BB, et al (2003). Trans-activation of heparanase promoter by ETS transcription factors. Oncogene, 22, 919-23.
30. Lv M, Li B, Li Y, et al (2011). Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 12, 2411-7.
31. Monte D, Baert JL, Laget MP, et al (1995). Transcription factors of the PEA3 group in mammary cancer. Ann Endocrinol, 56, 547-51 (in French).
32. Monte D, Coutte L, Baert JL, et al (1995). Molecular characterization of the ets-related human transcription factor ER81. Oncogene, 11, 771-9.
33. Netzer S, Leenders F, Dumont P, et al (2002). Ectopic expression of the ets transcription factor ER81 in transgenic mouse mammary gland enhances both urokinase plasminogen activator and stromelysin-1 transcription. Transgenic Res, 11, 123-31.
34. Papoutsopoulou S, Janknecht R (2000). Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol, 20, 7300-10.
35. Shepherd TG, L Kockeritz, MR Szrajber, et al. (2001). The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol, 11, 1739-48.
36. Shin SD, Bosc G, Ingle JN, et al (2008). Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem, 105, 866-74.
37. Shin S, Kim TD, Jin F, et al (2009). Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res, 69, 8102-10.
38. Subik K, Lee JF, Baxter L, et al (2010). The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl), 4, 35-41.
39. Tomlins SA, Laxman B, Dhanasekaran SM, et al (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448, 595-9.
40. Vageli D, Ioannou MG, Koukoulis GK (2009). Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81- related pathway. Oncol Res, 17, 413-23.
41. Wang Y, Wang L, Chen Y, et al (2011). ER81 Expression in Breast Cancers and Hyperplasia. Patholog Res Int, 2011, 980513.
42. Yu T, Hou F, Liu M, et al (2012). Norcantharidin antiangiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer. Asian Pac J Cancer Prev, 13, 499-503.